VIRVir Biotechnology Inc
VIR
Vir Biotechnology Inc6,433
Mkt Cap
$1.05BVolume
9.5M52W High
$9.8452W Low
$4.16PE Ratio
-2.09VIR Fundamentals
Price
$7.43Prev Close
$7.56Open
$7.5450D MA
$6.75Beta
1.54Avg. Volume
1.99MEPS (Annual)
-$3.83P/B
1.32Rev/Employee
$181,875.00$103.21
Earnings Recap
• Reported GAAP EPS of -$0.31 up 59.21% YoY • Reported revenue of $64.07M up 417.78% YoY • Based on current operating plans, Vir Biotechnology expects its cash, cash equivalents, and investments to fund operations into the second quarter of 2028, including effects of the Astellas collaboration.
Bullish
Vir Biotechnology advanced its pipeline with a strategic Astellas collaboration for VIR-5500 and Norgine licensing for hepatitis delta, bolstered by positive clinical data and an improved Q4 net loss.
Bearish
Vir Biotechnology's full year 2025 cash and investments declined by $313.8M, and full year revenue decreased, highlighting a reliance on volatile license and collaboration agreements.